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Abstract: We show that natural products target proteins with a
high number of protein-protein functional interactions (high
biological network connectivity) and that these protein targets
have higher network connectivity than disease genes. This feature
may facilitate disruption of essential biological pathways, resulting
in competitor death. This result also suggests that additional
sources of small molecules will be required to discover drugs
targeting the root causes of human disease in the future.
Naturally occurring small molecules (“natural products”) or their
derivativescompriseasubstantialfractionofthecurrentpharmacopeia.
1,2
We wished to understand the relationship of protein targets of
natural products to heritable disease genes by comparing the
biological network connectivities (functional connections between
genes and gene products, e.g., protein/protein interactions) of these
targets and genes. Understanding such relationships might facilitate
future drug discovery, e.g., by determining whether natural products
are intrinsically suited for targeting disease genes and whether their
enrichment among current drugs reﬂects a historical focus or special
properties intrinsic to these molecules. We seek to learn, in a data-
driven way, whether or not the propensity of natural products for
interaction with biological targets is an advantage for probe or drug
discovery directed at the genes determined to be causal for human
disease.
Discussions about the past and future roles of natural products
in drug discovery continue while large-scale screening of pure
synthetic compounds has come to dominate the drug-discovery
landscape.
1,3 In many cases, such discussions focus on the chemical
structures of natural products and how they are similar to or different
from synthetic compounds,
2 particularly in light of “rules” to guide
drug-discovery efforts.
4,5 Other perspectives have focused on the
accessibility of these molecules, their relative difﬁculty of synthetic
modiﬁcation, and whether they are suited to prevailing screening
methods within the pharmaceutical industry.
1,3 Here, we investigate
natural products from a different perspective, bioinformatic analysis
of natural product targets.
Earlier studies show that disease genes (genes having polymor-
phisms within the human population that correlate with the
frequency of disease; e.g., the CFTR gene and cystic ﬁbrosis) have
intermediate connectivities in biological networks.
6,7 Both highly
connected and less connected genes are less likely to be associated
with disease phenotypes. The network connectivity of natural
product targets is presumed to be high; however, we believe this is
the ﬁrst computational study of network connectivity of natural
product targets compared with disease genes. We used the publicly
available STRING database of protein/protein associations
8 as a
foundation for analyzing network connectivities.
9,10 In our analysis,
we included only proteins with at least one connection and only
connections with very high conﬁdence scores assigned by STRING
(g0.9).
To identify natural product targets, we evaluated a commercial
database of natural products and targets from GVKBio.
11 We
standardized 5581 target names and species to human proteins, as
either direct natural product targets or orthologous human target
proteins, and mapped these targets to 946 human proteins with
connections in STRING. For human disease genes, we combined
3655 genes contained in the OMIM Morbid Map
12 with 1580 genes
from a genome-wide association study SNP database
13 and mapped
these to 2681 human proteins with connections in STRING.
We assessed the distributions of protein connectivities among
all STRING proteins with at least one connection, natural product
targets mapped to STRING proteins, and heritable disease genes
mapped to STRING proteins (Figure 1a). Our analysis conﬁrms
that STRING proteins mapped from disease genes display inter-
mediate connectivity in biological networks. In contrast, STRING
proteins mapped from natural product targets are enriched for more
highly connected proteins compared to both STRING proteins
mapped from disease genes and all STRING proteins. We used a
Kolmogorov-Smirnov goodness-of-ﬁt test
14 between cumulative
connectivity distributions (Figure 1b) to assess the statistical
signiﬁcance of this ﬁnding. Differences in distributions of network
connectivities for natural product targets vs disease genes (p ) 2.6
× 10-15), natural product targets vs all STRING proteins (p ) 1.9
× 10-39), and disease genes vs all STRING proteins (p ) 2.8 ×
10-15) were all statistically signiﬁcant.
The STRING database contains potential targets from multiple
species and connects proteins using multiple lines of evidence,
including experimental evidence, pathway database information,
and connections from literature text mining. We performed several
control comparisons to examine the impact of these factors on our
ﬁndings. First, when clusters of orthologous groups (COGs) of
proteins were used as network nodes, these distributions and their
relative relationships were essentially unchanged (see Supplemen-
tary Figure S1). Second, when we restricted STRING connections
to those obtained from experimental evidence, we found that the
relative connectivities of the three groups were unchanged and each
remained signiﬁcantly different from the others (see Supplementary
Figure S2). Third, when we restricted STRING connections to those
obtained by mining pathway databases, we observe much more
similar connectivities between all proteins and disease-associated
proteins, while natural product targets remain more connected than
both (see Supplementary Figure S3).
The GVKBio database contains some protein targets that are only
weakly or nonselectively inhibited. Therefore, we undertook an
annotation of the primary literature by searching for and capturing
experimentally conﬁrmed natural product/protein interactions, with
a particular focus on highly potent and selective natural products.
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the primary literature (see Supporting Information). Protein names
were standardized to human genes/proteins or mapped to human
orthologues. We analyzed the distribution of protein connectivities
of these targets using the STRING database as before and found
that these protein targets exhibit even higher connectivities than
the larger GVKBio set (Figure 2a), further supporting the notion
that natural products target highly connected biological networks
to disrupt cellular functions in competing organisms. The natural
products that target these highly connected networks display a wide
variety of structural features (Figure 2b), suggesting that it is
unlikely that there is a single structural feature in natural products
that speciﬁcally targets highly connected biological nodes. As an
alternative method to approach the issue of target “quality” among
interactions in the GVKBio database, we analyzed the subset of
GVKBio small molecule/protein activities with reported effective
concentrations of half-maximal effect (EC50) in the nanomolar
range or below (<10-7.5 M). This subset comprises 10.4% of the
full GVKBio data set, corresponding to high-potency interactions,
and their network connectivities were essentially the same as using
the larger GVKBio data set (see Supplementary Figure S4),
suggesting that the observation that natural product targets are more
highly connected is not skewed by targets that are only weakly or
nonselectively inhibited.
Our basic observation that natural product targets are more
connected than disease genes compares a collection of targets of
small molecules (natural products) with a collection of proteins
obtained by mapping disease-implicated genes onto the proteome.
Therefore, we sought to examine whether other small-molecule
targets exhibit similarly high connectivities. To test this, we
Figure 1. (a) Connectivity summary of different protein groups: all human
proteins in STRING database (blue: n ) 8799; median ) 5; mean ) 11.7),
disease-associated proteins (green: n ) 2681; median ) 6; mean ) 14.0),
natural product targets (red: n ) 946; median ) 11; mean ) 22.5). (b)
Cumulative connectivity distributions.
Figure 2. (a) Comparison of cumulative connectivity distributions between
targets of 76 manually selected natural products (gold: n ) 38; median )
32.5; mean ) 48.5) and the database of natural products (red; same as Figure
1b). (b) Representative natural products obtained from literature review,
grouped according to connectivity associated with the target.
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in ChEMBL.
15 In this analysis, we identiﬁed the unique human
targets in ChEMBL and removed those targets already in our list
of natural product targets from GVKBio, giving a set of proteins
targeted by only non-natural product small molecules. Consistent
with the idea that proteins that are targets of natural products are
more highly connected than other proteins, these ChEMBL targets
exhibit intermediate connectivity between targets of natural products
and proteins encoded by disease genes (Figure 3).
Finally, we examined the targets of approved drugs listed in
DrugBank
16 to determine whether their connectivity distribution
is more similar to that of targets of natural products than to that of
human disease genes. We examined the subset of approved drug
targets that are not also natural product targets in GVKBio. We
observe that approVed drug targets that are not also natural product
targets exhibit a connectiVity distribution much closer to the case
for human disease genes than natural product targets, which remain
the most highly connected targets (Figure 4). These results suggest
that synthetic compounds that target human proteins are accessing
targets with a lower degree of connectivity than natural products.
In further support of the idea that disease genes, which encode
conceptually and in practice attractive drug targets, exhibit inter-
mediate or low connectivity, we note that G-protein coupled
receptors, estimated to be more than 25% of all drug targets,
17
represent one of the least connected subgroups in STRING, with a
connectivity distribution much lower than that of STRING as a
whole (see Supplementary Figure S5).
Overall, our results indicate that targets of natural products are highly
connected, much more so than genes implicated in human disease,
which exhibit intermediate connectivity, and more so even than other
groups of small-molecule targets. This ﬁnding may indicate that natural
products tend to target proteins more essential to an organism than
are disease genes. This result is logical, as many natural products
function as basic defense mechanisms against invaders in the absence
of tissue specialization or an advanced immune response. This type
of nonspeciﬁc defense often results in the death of the invading
organism to ensure the producing organism’s survival. Therefore, it is
not surprising to ﬁnd that natural products would target more highly
connected proteins, interrupting essential protein activities of the
invader. Here, we present computational evidence that this “intuition”
is correct. Our results also imply that natural products, as a group,
may not display enough versatility to be suitable for treatment of all
heritable human diseases. If this is the case, additional sources of small
molecules will be required to generate treatments that target the root
causes of disease.
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Figure 3. Comparison of cumulative connectivity distributions between
other small-molecule targets from ChEMBL
15 (gold: n ) 729; median )
8; mean ) 17.4), natural product targets (red; same as Figure 1b), and human
disease genes (green; same as Figure 1b).
Figure 4. Comparison of cumulative connectivity distributions between
approved drug targets from DrugBank
16 (gold: n ) 731; median ) 7; mean
) 14.9), natural product targets (red; same as Figure 1b), and human disease
genes (green; same as Figure 1b).
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